Advertisement

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

A study has found that taking Femara for 10 years instead of 5 reduces the risk of recurrence of a new breast cancer being diagnosed in the contralateral breast.

 New England Journal of Medicine

click me